| Document |
Document Title |
|
JP4618548B2 |
|
|
JP4597481B2 |
The present invention relates to a novel method for providing a cathartic effort to a patient in need of cathartic induction, which comprises administering to the patient a cathartic-inducing effective amount of halogenated bioactive lip...
|
|
JP4591778B2 |
|
|
JP4563636B2 |
A prostaglandin derivative represented by the formula: wherein X is a halogen atom in the alpha - or beta -position, Y is an ethylene group, a vinylene group or an ethynylene group, A is a group represented by the formula: O(CH2)n, S(O)p...
|
|
JP4556511B2 |
|
|
JP4510300B2 |
An enantiomerically enriched compound of formula (1), wherein Ar is phenyl optionally substituted with one or more groups selected from haloalkyl, alkyl and halide. This compound can be isolated in crystalline form, and used in the prepa...
|
|
JP4493856B2 |
A propargylic alcohol, enriched in the (R)-enantiomer, has formula (I) wherein R is C1-4 alkoxy, halogen, or C1-4 alkyl optionally substituted by OH or halogen. This may be prepared by the steps of: (a) enantioselective (R)-esterificatio...
|
|
JP4477504B2 |
A drug which contains as an active ingredient a prostaglandin derivative represented by the following formula, a pharmaceutically acceptable salt thereof, or a hydrate of either. The drug is reduced in side effects and has an antipruriti...
|
|
JP4475943B2 |
Disclosed are processes for the synthesis and purification of prostaglandins and analogues thereof, especially analogues of PGF 2± .
|
|
JP2010053149A |
To provide a purification method for a latanoprost and a high-purity latanoprost.The method for purifying the latanoprost is conducted by HPLC characterized by use of a mixture containing one ore more hydrocarbons, one or more alcohols, ...
|
|
JP4409767B2 |
A sleep-inducing preparation which comprises as an effective ingredient a prostaglandin derivative represented by the formula: wherein X is a halogen atom, Y is a group represented by (CH2)m, a cis-vinylene group or a phenylene group, Z ...
|
|
JP2010006835A |
To provide a preventive and/or therapeutic agent for bone loss diseases (primary osteoporosis, secondary osteoporosis, carcinoses bone metastasis, hypercalcemia, Paget's disease, bone deletion, bone disorders of osteonecrosis, osteogenes...
|
|
JP4394170B2 |
Compounds of the general formula A-X1-NO2, or their pharmaceutical compositions, wherein A contains a prostaglandin residue, X1 is a bivalent connecting bridge.
|
|
JP4386581B2 |
A process for producing a purified prostaglandin derivative having a high purity which comprises adding an alkene (1) to cyclopentenone (2) under the action of an alkyl lithium and an organic copper reactant to give an adduct; reacting t...
|
|
JP4354644B2 |
A sleep-inducing preparation which comprises as an effective ingredient a prostaglandin derivative represented by the formula: wherein X is a halogen atom, Y is a group represented by (CH2)m, a cis-vinylene group or a phenylene group, Z ...
|
|
JP4351630B2 |
A prostaglandin derivative represented by Formula (I) : wherein X is a halogen atom in the alpha - or beta -substitution, Y is an ethylene group, a vinylene group or an ethynylene group, R<1> is a C3-10 cycloalkyl group, a C3-10 cycloalk...
|
|
JP4275194B2 |
The invention relates to (+/-) trans-2-[-4(1-hydroxyhexyl) phenyl]-5-oxocyclopentaneheptanoic acid, and ester and unsaturated derivatives thereof, prostaglandin derivatives. More particularly, the present invention concerns compounds of ...
|
|
JP4273407B2 |
A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP 4 agonist as an active ingredient. An EP 4 agonist, in which includes a compound p...
|
|
JP4248022B2 |
15-Fluoro substituted analogs of PGF2alpha and methods of their use in treating glaucoma and ocular hypertension are disclosed.
|
|
JP2009501150A |
Nitroderivatives of prostaglandin amides having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.
|
|
JP2009500315A |
Nitroderivatives of fluoroprostaglandins having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.
|
|
JP4193197B2 |
|
|
JP4183943B2 |
Disclosed is a method for promoting bile secretion, which comprises administering and effective amount of a certain 15-keto-prostaglandin compound to a subject having a disease or condition associated with bile secretion deficient. Also ...
|
|
JP4153998B2 |
A hydroxy-1-alkyne is reacted with a tin hydride compound, and the obtained (E,Z)-hydroxyvinylstannanes are separated to give the (E)-substance which is further converted to a vinylcopper complex shown by followed by the conjugate additi...
|
|
JP2008214351A |
To provide a method for applying a useful compound for high ocular pressure, especially for the treatment of glaucoma, and a medicinal composition containing the compound.In this method, a prostaglandin derivative represented by the form...
|
|
JP2008533158A |
Disclosed herein is a method comprising administering a compound to a mammal suffering from an inflammatory bowel disease for the treatment of said disease, said compound having a structure according to Formula I wherein X, Y, B, R2, R3,...
|
|
JP4123568B2 |
|
|
JP2008037782A |
To provide a method for producing prostaglandin derivatives typified by latanoprost, efficiently, at a low cost and safely.The method for producing prostaglandin derivatives represented by general formula (1) (wherein Ph is phenyl; and R...
|
|
JP4044967B2 |
The present invention provides 11,15-O-dialkyl prostaglandin E derivatives of formula (I) (wherein all symbols are as described in Specification), or non-toxic salts thereof or cyclodextrin clathrates thereof, processes for the preparati...
|
|
JP4029251B2 |
|
|
JP4020449B2 |
|
|
JP4004109B2 |
|
|
JP4000599B1 |
A substituted cyclopentene derivative of formula (V): wherein X1 is ( alpha -OZa, beta -H) or ( alpha -H, beta -OZa), X3 is ( alpha -OZd, beta -H), ( alpha -H, beta -OZd), or oxygen atom, each of Za and Zd, which may be the same or diffe...
|
|
JP3994074B2 |
A fluorine-containing prostaglandin derivative of the formula (1) or a salt thereof, and a medicine containing it, particularly, as a preventive or therapeutic medicine for an eye disease: wherein A is a vinylene group or the like, R<1> ...
|
|
JP3989377B2 |
The present invention relates to a process for effectively preparing prostaglanin derivatives and to a stereospecific alkyl halide containing 15S-alcohol group as a starting material.
|
|
JP3984283B2 |
Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.
|
|
JP2007515467A |
A compound selected from one of the following: or a salt, solvate, chemically protected form or prodrug thereof, and its use in treating conditions alleviated by agonism of an EP2 receptor.
|
|
JP2007512252A |
Disclosed herein are compositions comprising an amide related to a prostaglandin and an amine wherein the amine is selected from the group consisting of epinephrine, dopamine, serotonin, and analogs or prodrugs thereof. Also disclosed ar...
|
|
JP2007505110A |
The invention relates to the use of cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and carbamoyloxy as therapeutic agents e.g. as ocular hypotensives. The compounds used in accordance with the invention are represented by the follo...
|
|
JP3878701B2 |
To industrially advantageously obtain the subject compound useful as an intermediate for prostaglandins simply and efficiently by reacting a specific propyne dianion with a specific ketone and quenching the reaction product in an acidic ...
|
|
JP2007016050A |
To provide a new process for preparing 15(S)-prostaglandin intermediates.The process for preparing 15(S)-prostaglandin intermediates compounds (IV) and (XVIII) comprises: a step (1) of contacting the corresponding enone with (-)-chlorodi...
|
|
JP3865842B2 |
To obtain the subject compound showing smaller side effects than the conventional ones, potent and highly lasting anti-ulcer effects, and useful as a medicine by providing a triple bond and phenoxy group or the like each at a specific si...
|
|
JP3865843B2 |
To obtain the subject new compound having slighter adverse effects than existing prostaglandin E1 analog and strong antiulcer action excellent in durability. This compound is shown by formula I {R is H or a 1-4C alkyl; R1 is a group of f...
|
|
JP2839798B6 |
|
|
JPWO2004074240A1 |
formula(In the formula, X represents a halogen atom, Y represents an ethylene group, a vinylene group or an ethynylene group, and Z represents a-(CH).2)m-, -O (CH2)n-Or -S (O)p-(CH2)n-(M indicates an integer from 0 to 3, n indicates an i...
|
|
JP3778563B2 |
The invention relates to 7-[5-hydroxy-2-(hydroxyhydrocarbyl or heteroatom-substituted hydroxy hydrocarbyl)-3-hydroxy-cyclopentyl(enyl)] heptanoic or heptenoic acids and derivatives of said acids, wherein one or more of said hydroxy group...
|
|
JP2005330191A |
To provide a method for producing a prostaglandin derivative, the prostaglandin derivative and an intermediate compound therefor, especially a method for producing a δ-12-prostaglandin J2 derivative using a new method for chemical synth...
|
|
JP3720861B2 |
PURPOSE: To obtain the subject compound inhibiting cell migration stimulated by chemokine and useful as a therapeutic medicine for arterial sclerosis by reacting an organic lithium compound with an organic copper compound, a cyclopenteno...
|
|
JP3717053B2 |
An improved method is described for making 9-deoxy-PGF1-type compounds. In contrast to the prior art, the method is stereoselective and requires fewer steps than the known methods for making these compounds.
|
|
JP3703004B2 |
To obtain a new 5-thia-ω-substituted phenyl-prostaglandin E derivative. This 5-thia-ω-substituted phenyl-prostaglandin E derivative is a compound expressed by formula I {R1 is hydroxyl, a 1-6C alkyloxy or NR6R7 (R6, R7 are each indepen...
|
